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Summary
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Alzheimer's disease (AD) displays a long asymptomatic stage before dementia. We characterize
AD stage-associated molecular networks by profiling 14,513 proteins and 34,173 phosphosites in
human brain with mass spectrometry, highlighting 173 protein changes in 17 pathways. The
altered proteins are validated in two independent cohorts, showing partial RNA dependency.
Comparisons of brain tissue and cerebrospinal fluid proteomes reveal biomarker candidates.
Combining with 5xFAD mouse analysis, we determine 15 Aβ-correlated proteins (e.g., MDK,
NTN1, SMOC1, SLIT2 and HTRA1). 5xFAD shows a proteomic signature similar to symptomatic
AD but exhibits activation of autophagy and interferon response, and lacks human-specific
deleterious events, such as downregulation of neurotrophic factors and synaptic proteins. Multiomics integration prioritizes AD-related molecules and pathways, including amyloid cascade,
inflammation, complement, WNT signaling, TGFβ/BMP signaling, lipid metabolism, iron
homeostasis, and membrane transport. Some Aβ-correlated proteins are colocalized with amyloid
plaques. Thus, the multilayer omics approach identifies protein networks during AD progression.

Graphical Abstract
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By mass spectrometry-based proteomics and integrated multi-omics, Bai et al. reveal novel
proteins and molecular networks during Alzheimer’s disease progression and validate the proteins
in the 5xFAD mice. Further comparisons of brain tissue and cerebrospinal fluid proteomes identify
biomarker candidates.
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Alzheimer’s disease; TMT; mass spectrometry; proteomics; proteome; phosphoproteome;
transcriptome; RNA-seq; genomics; genome; brain tissue; cerebrospinal fluid; biomarker; systems
biology; multi-omics; disease network; mouse model; 5xFAD; Aβ; Tau; APOE; NTN1; Netrin;
UNC5C; MDK; SMOC1; ICAM1; complement
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Introduction
Alzheimer's disease (AD) is the most common type of dementia, imposing a substantial
burden to patients and the healthcare (Alzheimer's, 2015). Genetic analysis of AD patients
revealed three causative genes (APP, PSEN1 and PSEN2), several risk genes (APOE,
TREM2, and UNC5C) (Colonna and Wang, 2016; Guerreiro et al., 2013; Wetzel-Smith et
al., 2014), and more than 20 low-risk genetic loci (Kunkle et al., 2019; Lambert et al., 2013).
Biochemical studies discovered pathological hallmarks of Aβ plaques and Tau
neurofibrillary tangles in AD brain (Hyman et al., 2012). The resulting amyloid cascade and
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Tau hypotheses (Ballatore et al., 2007; Hardy and Selkoe, 2002) become central to AD
research. A large number of animal models have been developed to test these hypotheses,
but cannot fully recapitulate AD symptoms (LaFerla and Green, 2012; Sasaguri et al., 2017).
Current targeted therapeutic strategies have failed to slow down cognitive decline in AD
(Graham et al., 2017; Huang and Mucke, 2012), raising concerns about these hypotheses and
calling for a broad understanding of molecular and cellular components in AD brain, at both
asymptomatic and symptomatic stages during the disease progression (De Strooper and
Karran, 2016).

Author Manuscript

The advent of next-generation sequencing technologies for DNAs, RNAs and proteins
(Aebersold and Mann, 2016; Altelaar et al., 2013; Metzker, 2010), provides an
unprecedented opportunity to thoroughly characterize human specimens to elucidate disease
networks and novel therapeutic targets. Large-scale genomic analysis of AD is in progress
(https://www.niagads.org), and transcriptomic analysis constructed potential disease
networks (e.g. microglia-specific module) (Miller et al., 2008; Zhang et al., 2013), and
identified cell type specific alterations in AD (Mathys et al., 2019). The transcriptome,
however, is often not an accurate indicator of protein abundance (Liu et al., 2016), especially
in complex brain tissue (Sharma et al., 2015). For example, abnormal aggregation of APPcleaved Aβ peptide and phospho-Tau highlights substantial deregulation of posttranslational
events in AD (Taylor et al., 2002). Analysis of proteome in AD and during aging has been
attempted (Seyfried et al., 2017; Wingo et al., 2019). We performed a comprehensive
analysis of the aggregated proteome, detecting the deposition of U1 small nuclear
ribonucleoprotein (U1 snRNP) and a deficit of RNA splicing in AD brain (Bai et al., 2013;
Lutz and Peng, 2018). The study of aggregated subproteome motivates us to revisit the
whole proteome during the development of Alzheimer’s disease.

Author Manuscript

Here, we present a new paradigm of analyzing 14,513 proteins (12,018 genes) and 34,173
phosphosites (46,612 phosphopeptides) in different disease stages of AD, using the latest
multiplexed tandem-mass-tag (TMT) method and two-dimensional liquid chromatographytandem mass spectrometry (LC/LC-MS/MS) (Bai et al., 2017; Niu et al., 2017; Tan et al.,
2017; Wang et al., 2019). This ultra-deep analysis is further validated in two independent
AD cohorts, and in the 5xFAD mouse model. Protein changes are only partially consistent
with the corresponding RNA levels. Comparison of the human and mouse proteomes defines
their resemblance and difference. Finally, we integrate multi-omics datasets to prioritize
altered proteins/genes and pathways. A number of top-listed proteins emerge with the
appearance of amyloid plaques. In summary, these results provide a rich resource of
molecular alterations in AD and establish a crucial framework of disease networks/
pathways.

Author Manuscript

Results
Deep Proteomic and Phosphoproteomic Profiling of AD Progression
We developed a three-phase strategy to discover, validate and integrate multi-omics AD data
(Figure 1A). As clinical proteomic studies are often affected by confounding factors, such as
postmortem interval (PMI) (Beach et al., 2015), we performed a survey of mouse brain
samples with PMI of 0, 3, and 12 hours. Only 364 (2.6%) out of 14,007 proteins were
Neuron. Author manuscript; available in PMC 2021 March 18.
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changed among different PMIs, whereas 4,736 (16.5%) out of 28,699 phosphopeptides were
altered in the comparisons (Data S1A and S1B). Thus we diminished the impact of
confounding factors by removing PMI-affected proteins and phosphoproteins, selecting
well-characterized specimens with very short PMI (3.0 ± 0.8 h) in the discovery study (Table
1 and Data S2A) (Beach et al., 2015), implementing additional quality control metrics to
discard samples compromised by protein degradation (Figure S1), and correcting for celltype composition bias during data analysis (see STAR method).

Author Manuscript
Author Manuscript

Using the multiplexed tandem-mass-tag (TMT) method and two-dimensional liquid
chromatography-tandem mass spectrometry (LC/LC-MS/MS) (Bai et al., 2017; Pagala et al.,
2015), we started with frontal cortical samples of 100 human cases, and selected 90 samples
of high quality for profiling whole proteome and phosphoproteome (Figure 1B and Figure
S1, Table 1 and Data S2A) in 5 equal groups: (i) controls with low pathology of plaques and
tangles (LPC), (ii) controls with high Aβ pathology but no detectable cognitive defects
(HPC) (Nelson et al., 2012), (iii) mild cognitive impairment (MCI) with Aβ pathology and a
slight but measurable defect in cognition (Hyman et al., 2012), (iv) late stage AD with high
pathology scores of plaques and tangles, and (v) progressive supranuclear palsy (PSP),
another neurodegenerative disorder of tauopathy (Williams and Lees, 2009). A pooling
strategy with replicates (Bai et al., 2013) was designed to simplify the analysis, dividing the
90 samples into 10 pools (Figures S1 and S2). Exhaustive LC/LC-MS/MS improved
quantitative accuracy and proteome coverage (Niu et al., 2017), quantifying 14,513 proteins
(12,018 genes, false discovery rate (FDR) < 1%, Data S2B), and 34,173 phosphosites
(46,612 phosphopeptides, FDR < 1%, Data S2C) (Figure 1B and Figures S3A-S3C). The
MS-measured Aβ peptide level is largely consistent with the results of plaque pathology in
the 5 groups of samples (Figure 1C). The data quality is further supported by high
reproducibility of replicates in clustering analysis (Figure 1D), principal component analysis
(Figure S3D), and correlation analysis (Figure S3E, R2 > 0.97 between replicates).

Author Manuscript

To explore proteome dynamics during AD progression, we used a stepwise pipeline (Figure
1E) to define 173 differentially expressed (DE) proteins (FDR < 20%) in 17 pathways,
adapted the weighted gene correlation network analysis (WGCNA) (Langfelder and
Horvath, 2008) to cluster these DE proteins, and interpreted the clusters with protein-protein
interaction (PPI) network. Three whole proteome clusters (termed WPC) were identified
from the analysis (Figure 1F), whereas a small number of proteins (n = 8) did not follow any
of these clusters (Data S3A). WPC1 (n = 50) displays an early increase in HPC and MCI and
a continuous accumulation in AD, including Aβ, TREM2 and CLU. These proteins are
enriched in 12 pathways of amyloid cascade, WNT signaling, TGFβ/BMP signaling, G
protein signaling, integrin pathway, innate immunity, adaptive immunity, cytoskeleton and
extracellular matrix, membrane transport, lipid metabolism, protein folding and degradation,
and synaptic function (Figure 1G). WPC2 proteins (n = 88) are relatively stable in the stages
of HPC and MCI, but show a marked increase when progressing to AD, including MAPT
(tau) and complement components. WPC2 recapitulates all enriched pathways in WPC1, and
contains three additional pathways of cytokine signaling, complement and coagulation, and
iron homeostasis (Figure 1G). In contrast, WPC3 (n = 27) shows no obvious change in the
HPC and MCI, followed by a notable decrease in AD, identifying two more pathways of
neurotrophic factor signaling and mitochondrial function (Figure 1G). Furthermore, we
Neuron. Author manuscript; available in PMC 2021 March 18.
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integrated the DE proteins in each WPC pattern with the protein-protein interaction network
to define 11 functional modules, providing the evidence of protein-protein interaction to
support these enrichment pathways (Figure 1H and Data S3B). Importantly, among the 173
DE proteins in AD, 163 (94%) proteins show no significant changes in the PSP brain
displaying tauopathy but missing amyloid plaques, indicative of a high degree of AD
specificity (Data S3A).

Author Manuscript

As the majority of these altered proteins are novel, we validated the changes of 11 proteins
by western blotting in the pooled AD samples (Figure 1I), and performed two additional
large-scale validation analyses by TMT-LC/LC-MS/MS. First, we profiled 49 individual
human brain samples from the same Banner Sun cohort used for the pooled study (Data
S2A, Figure 2A), identifying 12,650 proteins across all samples (FDR < 1%). Out of the 173
DE proteins identified in the pooled analysis, 121 were re-detected in the individual samples
and divided into the WPC1-3 clusters. Consistently, 117 (97%) proteins displayed similar
patterns during AD progression (Figures S4A and S4B). Second, we profiled 80 brain
cortical samples from an independent Mount Sinai cohort (PMI 7.5 ± 5.4 h) and accepted the
proteomic results from 62 cases (23 normal control cases, and 39 AD cases, Data S4A,
Figure 2B), identifying 12,147 proteins shared by all samples. Among the 117 DE proteins
found in the Banner Sun cohort, 84 were reidentified in the Mount Sinai cohort, in which 58
(69%) showed consistent changes in AD (Figures 2C and 2D, Data S4B). Thus, the two
extensive TMT validation analyses strongly support reproducibility of our deep proteomics
studies.

Author Manuscript

To investigate the mechanisms underlying the protein changes in AD, we compared our AD
proteome datasets with a reported large-scale AD transcriptome dataset (Allen et al., 2016).
Among the 58 altered proteins in AD, almost all decreased proteins (89%, 8 out of 9
proteins) are associated with decreased RNA levels, but only 55% (27 out of 49 proteins) of
increased proteins link to upregulated transcripts (Figure 2D, Data S4B), suggesting that the
remaining 45% of increased proteins are regulated by posttranscriptional mechanisms.

Author Manuscript

To examine if these protein changes in the AD brain tissue are detectable as potential
biomarkers in cerebrospinal fluid (CSF), we performed deep proteomics profiling of CSF
samples (n = 13, 5 control and 8 AD cases, Figure 2E) and quantified 5,940 proteins (Data
S4C). The analysis detected 49 proteins from the 58 proteins changed in AD brain tissue, in
which a list of 8 proteins are consistently changed in the CSF samples (p < 0.05, Figure 2F,
Data S4D). In the list, 4 proteins (GPNMB, SMOC1, NPTX2 and VGF) have previously
been reported in AD CSF (Dayon et al., 2018; Huttenrauch et al., 2018; Llano et al., 2019;
Xiao et al., 2017), and the other 4 proteins (SLC39A12, SLC5A3, SLIT2 and STEAP3) are
novel biomarker candidates.
Phosphoproteome-derived Kinase Activities in AD
The phosphoproteome profiling identified 34,173 phosphosites (46,612 phosphopeptides) on
7,083 phosphoproteins (Data S2C, Figure S5A), and as expected microtubule-associated Tau
is the most elevated phosphoprotein in AD (Figure 3A). There are 25,698 (75%) pS, 7,216
(21%) pT, and 1,259 (4%) pY sites (Figure 3B). Reproducibility of replicates is verified by
clustering analysis (Figure 3C), principal component analysis (Figure S5B), and correlation
Neuron. Author manuscript; available in PMC 2021 March 18.
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analysis (Figure S5C, R2 > 0.75 between replicates). In the clustering analysis, the AD
group shows the largest distance from other groups, suggesting that AD harbors the most
dramatic change in phosphoproteome.

Author Manuscript

Similar to the whole proteome analysis, the stepwise computational pipeline was used to
identify 873 DE phosphopeptides (FDR < 20%, 398 proteins, Figure 3D) into four major
phosphopeptide clusters (PPC1-4, Figure 3E), whereas a small subset of phosphopeptides (n
= 22) did not fit into any of these clusters (Data S5A). PPC1 (n = 39) shows a steady
increase during AD development. PPC2 (n = 372) is stable in the HPC and MCI samples,
and dramatically increases in AD, reminiscent of the pathology of neurofibrillary tangles.
Notably, PPC2 contains 89 phosphopeptides from Tau (56 phosphosites, Data S5B), and 67
from osteopontin (SPP1), a glycoprotein regulating diverse biological processes (e.g.
immune response) (Wang and Denhardt, 2008). PPC3 (n = 104) increases slightly in the
HPC and MCI cases, and reduces in AD. PPC4 displays the downregulation of
phosphorylation in the HPC and MCI, followed by restoration in AD. Together, the PPC1-4
patterns demonstrate that protein phosphorylation is highly dynamic and actively remodeled
at different stages of AD.
We next examined the phosphoprotein pathways enriched in each PPC pattern (Figure 3F),
revealing two new pathways of splicing dysfunction and calcium hypotheses in AD.
Strikingly, there are only 11 proteins overlapped between the altered phosphoproteome (n =
398) and whole proteome (n = 173) (Figure 3G), indicating that the phosphoproteome
analysis represents a new layer of molecular regulation, complementing the landscape of the
whole proteome.

Author Manuscript

We then sought to derive kinase activities in the samples according to the levels of
phosphorylated substrates. The IKAP machine learning algorithm (Mischnik et al., 2016)
deduced the activities of 186 kinases, of which 28 are possibly changed, primarily in AD
(Figure 3H). For example, the CDK kinase activity could be computed from its known
substrates of MAPT, APP, LMNA, VIM, TLN1 and SQSTM1 (Figure 3I), and the GSK3
kinase activity was similarly inferred (Figure 3J). In total, the ABL, CDK, CAMK, GSK,
MAP3K, MAPK, PKC, and TTBK families, and 6 other kinases of PBK, FES, FYN,
MARK2, PKA (PRKACA), and PRKDC were likely activated in AD. Remarkably, this list
essentially covers all previously known Tau kinases (n = ~11) (Wang and Mandelkow,
2016).

Author Manuscript

Finally, we examined the levels of the possibly activated 28 kinases and related family
members in the whole proteome and phosphoproteome. Although the vast majority of
kinases (except MAP3K6) do not change at the whole protein levels (Data S2B), some of the
MAP kinase cascades exhibit a marked increase in phosphorylation, including four
sequentially activated families: MAP4K (e.g. MAP4K4), MAP3K (e.g. ARAF and
MAP3K12), MAP2K (e.g. MAP2K6), and MAPK (e.g. MAPK1/ERK2) (Figure 3K)
(Keshet and Seger, 2010). Moreover, the dual specificity protein phosphatase 6 (DUSP6), a
negative regulator of MAPK signaling, is significantly reduced in AD (Figure 3K).
Collectively, these multilevel proteomic analyses suggest the activation of MAP kinase
signaling that is implicated in AD pathogenesis (Kim and Choi, 2010).
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To explore molecular events induced by Aβ accumulation, we identified a list of 28 Aβcorrelated DE proteins in the whole proteome datasets from both Banner Sun and Mount
Sinai cohorts (FDR < 10%, Figures 4A-4C). The Aβ level is based on its fully tryptic
peptide (LVFFAEDVGSNK, Figure 4A), increasing ~7-8-fold from low pathology control
cases to AD, which correlates well with the plaque pathology in brain tissue. Since this
peptide can be generated from either Aβ or the full length APP, we examined the absolute
abundance of Aβ and APP by corresponding spectral counts. While this Aβ-derived peptide
has 35 spectral counts, APP has more than 30 tryptic peptides outside the Aβ region, which
have only 5 average spectral counts (Data S2B), indicating that Aβ is much more abundant
than APP in the samples. Moreover, MS quantification of the non-Aβ APP peptides shows
no significant change in AD. Thus, the selected peptide is a surrogate for Aβ, which was
also previously used for Aβ quantification by mass spectrometry (Seyfried et al., 2017).

Author Manuscript

We then evaluated the cause and effect relationships of the Aβ-correlated proteins in the
5xFAD model (Oakley et al., 2006) by analyzing a total of 16,128 proteins (11,573 proteins
across all samples, FDR < 1%) in the cortex of 5xFAD and wild type (WT) mice (3, 6 and
12 months of age, Figure 4D, Data S6A). In the 28 proteins, 23 were identified in all mice,
and 15 (65%) are consistently increased in the animals (Figure 4E, Data S6B), including
MDK, NTN1, CTHRC1, NTN3, SMOC1, SFRP1, OLFML3, SLIT2, HTRA1, FLT1,
SLIT3, CLU, ICAM1, LSP1, and C4B. Among the 15 proteins, only 4 (27%, OLFML3,
CLU, ICAM1 and C4B) proteins are linked to RNA upregulation (Figure 4E) based on
RNA-seq analysis (Data S6C), indicating that most Aβ-correlated proteins in 5xFAD are
regulated by posttranscriptional mechanisms.

Author Manuscript

Genetically modified mice cannot fully mimic AD and are often viewed as a model of AD
asymptomatic stage (LaFerla and Green, 2012). To test this idea, we compared the mouse
DE proteome (5xFAD/WT) with different human group DE proteome (HPC/LPC, MCI/
LPC, and AD/LPC, Figure 5A). Interestingly, 5xFAD (12 months of age) shares 97, 89, and
169 protein alterations with HPC, MCI and AD, respectively, The results implicate that
5xFAD has the most similar proteome to the late stage of AD, but not the early stage of AD
as previously anticipated (Ashe and Zahs, 2010).

Author Manuscript

Further examination of the DE proteomes in AD cases and 5xFAD mice reveals 37 humanspecific, and 69 5xFAD-specific DE proteins (Data S6D and S6E). In the human-specific DE
proteins, some synaptic proteins (e.g. CAMKK2 and NPTX2) and neuroprotective factors
(e.g. VGF and BDNF) are significantly reduced in AD, but not in the mice (Figure 5B).
Intriguingly, the 5xFAD-specific DE proteins might render different response to Aβ insult.
For example, lysosome/autophagy pathway proteins (e.g. LAMP1 and HEXB) are highly
enriched and increased (Figure 5C). Autophagy is essential to clear damaged organelles and
aggregated proteins; and enhanced autophagy might reduce AD-related pathology and
reverse memory deficit in mice (Nixon, 2013). Defective autophagy is usually accompanied
by the accumulation of the SQSTM1/p62 protein (Moscat and Diaz-Meco, 2009). Indeed,
p62 is accumulated in AD, but not in 5xFAD. Moreover, interferon response is markedly
increased in 5xFAD but not in AD (Figure 5C). Interferons is a class of cytokines with
profound neuroprotective or neurotoxic properties, which are dependent on relative
Neuron. Author manuscript; available in PMC 2021 March 18.
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interferon levels and cellular context (Schwartz and Deczkowska, 2016). For example, lack
of neuronal interferon-β signaling in mice was reported to block late-stage autophagy,
resulting in sporadic Lewy body accumulation and dementia (Ejlerskov et al., 2015). Thus,
the species-specific DE proteins may represent different magnitude of proteome remodeling
under the pathological conditions in human and mice.
Pathway Ranking and Top-ranked Proteins in Amyloid Plaque Pathology

Author Manuscript
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Integration of genomic data and gene expression information has proven powerful for
determining potential causative pathways in Alzheimer’s disease (Zhang et al., 2013). We
extended this concept by combining all major dimensional AD datasets to rank genes/
proteins and pathways, using order statistics (Aerts et al., 2006) and gene set enrichment
analysis (GSEA) (Subramanian et al., 2005) (Figure 6A). We included 7 datasets: MCI
whole proteome, AD whole proteome, phosphoproteome, and aggregated proteome (Bai et
al., 2013; Lutz and Peng, 2018), genome-wide association analysis (Lambert et al., 2013),
transcriptome (Allen et al., 2016), and protein-protein interactome (Huttlin et al., 2017). The
integrative protein ranking is based on all 7 datasets (Figure 6B, Data S7A), with APP,
APOE, and MAPT as the top 3 of the list, consistent with our current understanding of AD
pathogenesis. We then prioritized signaling pathways by GSEA, identifying 16 pathways
(FDR < 20%, Figure 6C), collectively classified into 4 major categories of amyloid and Tau
pathways, inflammation, growth and development, as well as metabolism and membrane
transport. Moreover, subcellular localization analysis indicates that the high-ranked proteins
are exceedingly enriched in secreted subproteome (secretome) and cell surface subproteome
(FDR < 10%, Figure 6D). For instance, in the top 200 proteins (Data S7B), 42% (n = 83) are
secretory proteins; and 20% (n = 40) are cell surface proteins. Moreover, other secretory
locations, such as vesicle lumen, secretory granule lumen, and Golgi lumen, are also
enriched in this analysis. The results suggest that the secreted and cell surface subproteomes
are particularly perturbed in AD, which might have a strong impact on cell communication.
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We then examined if highly ranked, Aβ-correlated proteins are associated with amyloid
plaque pathology. Indeed, immunohistochemistry experiments show that MDK, NTN1,
SMOC1, and ICAM1 are obviously accumulated in some plaque structures of AD,
compared to normal control cases (Figure 7A). When co-stained with Aβ in
immunofluorescence analysis, MDK and NTN1 are highly colocalized with Aβ plaques,
while SMOC1 and ICAM1 are partially colocalized in the plaque areas (Figure 7B). In
addition, we also analyzed complement protein C4B in human cases and identified both
amyloidopathy and angiopathy (Figure S6), supporting that the elevation of C4B is unlikely
due to blood contamination in human postmortem brain samples. In the 5xFAD model, the
plaque localization of MDK, NTN1, SMOC1 and ICAM1 is recapitulated in the brain
(Figures 7C and 7D), and the accumulation of these proteins is validated by Western blotting
(Figures 7E). Finally, we explored if these proteins physically interact with Aβ using an
affinity binding assay. The four highly purified recombinant proteins, biotin-labeled Aβ40
and a scrambled control peptide were obtained for the assay (Figure 7F). Clearly, MDK and
NTN1 directly binds to the Aβ40 column, but not to the control column, while the other two
proteins (SMOC1 and ICAM1) show no binding to Aβ40 in this assay (Figure 7G).
Collectively, these results indicate these Aβ-correlated proteins are colocalized with Aβ in
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the amyloid plaques, with MDK and NTN1 showing direct Aβ-binding, implicating that
they may function together in the AD brain.

Discussion
Achievement of Genome-wide Brain Proteomics Data in AD

Author Manuscript

Our deep, multilayer proteomic analyses reveal highly confident lists of altered key proteins
and phosphoproteins in both AD and the related 5xFAD model, and prioritize molecular
alterations by multi-omics datasets with a comprehensive computational pipeline, providing
novel insights into the proteins/pathways associated with AD. For example, when the 58 DE
proteins were searched in PubMed database, only 13 (23%) proteins were reported in at least
10 AD-related papers (Figure S7A). The acquisition of such rich proteomic information is
largely attributed to the access to high quality AD brain tissue (Beach et al., 2015) and the
strength of the optimized mass spectrometry-based proteomics platform, including multiplex
TMT isobaric labeling (Niu et al., 2017), extensive long gradient LC/LC coupled with high
resolution MS/MS analysis (Wang et al., 2015), a refined phosphopeptide enrichment
method (Tan et al., 2015), and a newly developed tag-based database JUMP search program
(Li et al., 2016; Wang et al., 2014). As regulatory proteins are central players in cells but
often exist at low abundance, the high coverage of proteome has become extremely
important to uncover those proteins. In addition, the collection of multilayer proteome
datasets, such as whole proteome, phosphoproteome, and aggregated subproteome (Bai et
al., 2013), moves toward a more complete view of proteotype (defined as the state of a
proteome associated with a specific phenotype) (Aebersold and Mann, 2016) to interpret
Alzheimer’s disease phenotypes.

Author Manuscript
Author Manuscript

The protein level in the AD brain tissue is controlled by the mechanisms of transcription,
translation and protein degradation (Liu et al., 2016). Out of the 58 DE proteins detected in
AD, 35 proteins are linked to corresponding RNA alterations, and 23 proteins appear to be
independent of transcriptional regulation (Figure 2D), in which 9 proteins (MDK, NTN1,
CTHRC1, SMOC1, SFRP1, SLIT2, HTRA1, SLIT3, and LSP1) are highly correlated with
Aβ in AD cases (Figure 4). Consistently, these 9 proteins are also demonstrated to increase
in the brain of 5xFAD mice by proteome profiling, and their related RNA levels do not
display upregulation with statistical significance in the RNA-seq analysis. Further
experiments show the plaque localization of MDK, NTN1 and SMOC1 in human and the
mouse model, and direct Aβ-binding of MDK and NTN1 (Figure 7). Additional evidence
comes from a recent proteomics study of amyloid plaques isolated by laser-capture
microdissection (Xiong et al., 2019), confirming 5 proteins (MDK, NTN1, SMOC1, SLIT2,
and HTRA1) in the plaque areas. Therefore, the protein level in AD brain is regulated by
both transcriptional and posttranslational mechanisms, which are not mutually exclusive. It
is possible that plaque association slows down the turnover of some proteins, which at least
partially contributes to their accumulation in AD.
Compensatory Protective Feedback at the Asymptomatic Stage of AD
Clinically, there is a long, prodromal stage in AD prior to the irreversibly progressive decline
of cognition (Hyman et al., 2012). A compelling concept is that initial Aβ accumulation may
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induce a compensatory feedback that is protective to attenuate the toxic Aβ insult, whereas a
vicious feedforward may require additional toxic factors to override the protection, leading
to irreversible degeneration (De Strooper and Karran, 2016). In this conceptual frame, we
discuss potential roles of the identified proteins in AD by our deep MS analysis (Figure
S7B).
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Our proteomic analyses identify multiple protein patterns (WPC1-3), dependent on different
disease stages. Only WPC1 displays early upregulation in the prodromal AD (HPC and
MCI). For example, NTN1/Netrin-1 and NTN3/Netrin-3 are highly correlated with Aβ in
human, and are induced in the 5xFAD mice. It has been reported that Netrin-1
overexpression reduces the Aβ level in an AD mouse model (PDAβPPSwe/Ind), and
intracerebroventricular injection of Netrin-1 enhances working memory in the mice
(Spilman et al., 2016). Interestingly, the Netrin-1 receptor UNC5C is an AD risk gene
(Wetzel-Smith et al., 2014). Aberrant UNC5C has been reported to activate cell death
signaling in cell culture, but netrin-1 may bind to UNC5C on the cell surface to suppress
UNC5C-induced cell death (Hashimoto et al., 2016). Midkine is also highly correlated with
Aβ in human cases and in the 5xFAD mice and it is proposed to antagonize Aβ cytotoxicity
(Herradon and Perez-Garcia, 2014).
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Surprisingly, we identified in WPC1 a large number of development pathway proteins,
including WNT5A, WNT5B, RSPO2, GPC5, and SULF2 in WNT signaling, as well as
BMP3 and SMOC1 in TGFβ/BMP signaling. Although the functions of these proteins are
largely dependent on cellular context, WNT signaling is generally viewed as a protective
mechanism for synaptic integrity and memory maintenance (Inestrosa and Varela-Nallar,
2014). For example, WNT5A stimulates the formation of dendrite spines and enhances
synaptic plasticity in mammalian brain (Varela-Nallar et al., 2010). Recent genetic studies
support the notion that WNT signaling is critical for synaptic function and neuronal
viability, and defective WNT signaling exacerbates plaque pathology in mice (Liu et al.,
2014). In microglia, WNT signaling may be activated by the AD risk gene TREM2 to
enhance microglial viability (Zheng et al., 2017). Consistently, we observed the upregulation
of OLFML3, a highly enriched marker for microglia (Crotti and Ransohoff, 2016). In
contrast, BMP signaling activation appears to be detrimental by impairing neurogenesis in
APP transgenic mice (Crews et al., 2010). Interestingly, both BMP3 and SMOC1 are
negative regulators of BMP signaling (Bragdon et al., 2011), implying that repression of
BMP signaling might play a positive role in maintaining neurogenesis in AD.
Increase of Detrimental Factors and Decrease of Protective Factors at the Symptomatic
Stage of AD

Author Manuscript

During the transition from MCI to AD, our proteomic analysis uncovers an upregulated
protein pattern (WPC2) and a downregulated pattern (WPC3), which may contain numerous
dysfunctional pathways to promote cognitive impairment and cell death. WPC2 includes
several complement proteins (e.g. C1R, C1S, C3, C4A and C4B). The complement system
functions with microglia to trim excess synapses during neurodevelopment, but can be
inappropriately activated to prune synapses in AD-related mouse models (Dejanovic et al.,
2018; Hong et al., 2016). C3 knockout mice exhibit less hippocampal synapse loss during
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normal aging. Further genetic crossing analysis support that C3 deficiency protects the mice
against synapse loss and memory decline in the APP/PS1 mice (Shi et al., 2017). Thus the
increased activity of the complement system may accelerate the development of AD
symptoms.
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WPC2 also contains numerous cytoskeletal proteins, as exemplified by tau that is
hyperphosphorylated and aggregated to contribute to neurodegeneration (Ballatore et al.,
2007). Aβ is proposed to initiate the conversion of tau from the normal to toxic form, which
mediates the Aβ toxicity at the synapse (Bloom, 2014). Moreover, the toxic tau may cause
defect in axonal transport along microtubules (Wang and Mandelkow, 2016), during which
iron export can be damaged, resulting in iron accumulation (Lei et al., 2012). Indeed,
clinical magnetic resonance imaging suggests that iron accumulates in AD brain (Raven et
al., 2013). In WPC2, we found significant upregulation of five proteins in iron homeostasis:
LTF (a major iron-binding transport protein), BDH2 (synthesizing siderophore that binds
iron), STEAP3 (transferrin-dependent iron uptake), and TSPO (transporting porphyrins and
heme) (Ganz, 2013). The excess iron metabolism may cause the accumulation of lipid
peroxidation products and reactive oxygen species, eventually leading to cell death. This
new form of programmed cell death has recently been termed ferroptosis, different from
apoptosis, necrosis and necroptosis (Stockwell et al., 2017). It is possible that the ironmediated ferroptosis plays a negative role in cell survival, contributing to neurodegeneration
in AD.
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In contrast, WPC3 proteins decrease in the AD brain. WPC3 contains several positive
neuroprotective factors, such as BDNF, VGF, NRN1, CRH and ADCYAP1. Interestingly,
these neurotrophic factors are assembled together around the “hub” BDNF in the PPI
network, indicating that they function in the same pathway. Multiple in vitro and in vivo
studies uniformly suggest their roles in neuroprotection (Han et al., 2014; Lin et al., 2015;
Lu et al., 2013; Pedersen et al., 2001). The decrease of these neuroprotective factors may
also lead to disease progression.
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In summary, our temporal proteomics data support the balance and antagonization of
positive and negative activities at different stages of AD. This work also illustrates the ability
of deep proteomics technologies to complement genomics and transcriptomics in AD
research. The comprehensive multi-omics measurements reveal crucial molecular networks/
pathways in AD. The AD and mouse model comparison identifies molecular similarity and
discrepancy in a global scale, providing evidence to explain the translational gap between
the mouse models and clinical trials. The rich data are anticipated to stimulate subsequent
hypothesis-driven research, provide potential CSF biomarkers, deepen our mechanistic
understanding of AD pathogenesis, and promote novel strategies for diagnosing and treating
this devastating disease.
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STAR METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be
fulfilled by the Lead Contact, Junmin Peng (junmin.peng@stjude.org). This study did not
generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS

Author Manuscript

Human Postmortem Brain Tissue and Cerebrospinal Fluid Samples—Human
postmortem brain tissue samples (frontal gyrus) were provided by the Brain and Body
Donation Program at Banner Sun Health Research Institute. Clinical and pathological
diagnoses were based on the established criteria (Beach et al., 2015). A total of 100 tissue
cases (Data S2A) were used for protein quality control analysis, 90 of which were finally
selected for the pooled explorative proteomics study. In addition, 49 individual cases (Data
S2A) were used for the validation proteomics study. Moreover, 20 CSF samples were used
for the pilot biomarker study, in which 13 were used in the final dataset. In addition, the
other independent cohort (80 cases, in which 62 cases were used in the final dataset; Data
S4A) was provided by the Alzheimer's Disease Research Center at Icahn School of
Medicine at Mount Sinai, with well characterized criteria for clinical and pathological
diagnoses (Wang et al., 2018).
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Mouse Brain Tissue—Heterozygous 5xFAD+/− transgenic mice that overexpress familial
AD mutant forms of human APP (the Swedish mutation, K670N/M671L; the Florida
mutation, I716V; and the London mutation, V717I) and PS1 (M146L, L286V) transgenes
under the transcriptional control of the neuron-specific mouse Thy-1 promoter (JAX stock
#006554), and littermate controls were used. Mice of 3, 6, and 12 months were used and
were of both sexes. Cortical brain tissue samples were dissected rapidly, frozen in liquid
nitrogen, and stored at −80° C. Mice were bred and maintained in a specific pathogen free
facility in the Animal Resource Center at St. Jude Children’s Research Hospital. All animal
protocols were approved by the Institutional Animal Care and Use Committee. Brain tissue
samples were dissected rapidly, frozen in liquid nitrogen, and stored at −80° C before
analysis.
METHOD DETAILS

Author Manuscript

Protein Extraction and Protein Quantification—Human or mouse brain samples
were lysed and the protein concentrations were quantified as previously described (Bai et al.,
2017). The frozen samples were weighed and homogenized in the lysis buffer (50 mM
HEPES, pH 8.5, 8 M urea, and 0.5% sodium deoxycholate, 100 μl buffer per 10 mg tissue)
with 1x PhosSTOP phosphatase inhibitor cocktail (Sigma-Aldrich). The human CSF
samples were extracted in the same buffer. Protein concentration was measured by the BCA
assay (Thermo Fisher) and then confirmed by Coomassie-stained short SDS gels.
Sample Quality and Pooling—One major challenge in studying human postmortem
brain tissue is that the specimens are usually associated with large biological variations (e.g.
age and gender), which are further confounded by a wide range of uncontrollable factors
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(Hynd et al., 2003), such as environmental elements (e.g. diet, lifestyle), antemortem and
pharmacological treatments, end-of-life illnesses, postmortem interval (PMI), and tissue
storage conditions. To reduce these biological variations, we followed a previously reported
pooling strategy (Bai et al., 2013), in which we successfully identified AD-specific U1
snRNP pathology in aggregated proteome. The pooling strategy averages biological
variations, increases statistical power, and reduces workload (Allison et al., 2006).
Simulation analysis indicates that 10 cases per pool can reach >90% statistical power
(Figure S2). The main caveat of pooling is that samples of poor quality (e.g. degraded or
contaminated) may affect the data of the entire pool. To address this problem, we
implemented the following steps to improve quality of pooled samples: (i) to select wellstored brain specimens diagnosed by consensus clinical and neuropathological criteria,
without large bias in race, age and gender; (ii) to obtain brain tissue with very short PMI (3.0
± 0.8 h) for the discovery study; and use mouse brain samples to test the effect of PMI on
the stability of proteome and phosphoproteome; (iii) to examine lysed brain samples with
SDS gels to confirm protein integrity prior to pooling (10 out of 100 samples excluded by
this step; Figure S1); (iv) to facilitate data analysis by incorporating samples during disease
progression (e.g. LPC, HPC, MCI and AD), as well as other neurodegenerative cases (e.g.
PSP with tauopathy); (v) to correct individual protein abundance affected by the cell type
composition change in different samples by a multivariate linear model; and (vi) to validate
proteins of interest in individual cases, and in an independent cohort.
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Protein Digestion and Tandem-Mass-Tag (TMT) Labeling—The analysis was
performed with a previously optimized protocol (Bai et al., 2017; Pagala et al., 2015). For
whole proteome and phosphoproteome profiling, quantified protein samples (~1 mg in the
lysis buffer with 8 M urea) for each TMT channel were proteolyzed with Lys-C (Wako,
1:100 w/w) at 21 °C for 2 h, diluted by 4-fold to reduce urea to 2 M for the addition of
trypsin (Promega, 1:50 w/w) to continue the digestion at 21 °C overnight. The insoluble
debris was kept in the lysates for the recovery of insoluble proteins. The digestion was
terminated by the addition of 1% trifluoroacetic acid. After centrifugation, the supernatant
was desalted with the Sep-Pak C18 cartridge (Waters), and then dried by Speedvac. Each
sample was resuspended in 50 mM HEPES (pH 8.5) for TMT labeling, and then mixed
equally, followed by desalting for the subsequent fractionation. For whole proteome analysis
alone, 0.1 mg protein per sample was used.
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Extensive Two Dimensional Liquid Chromatography-Tandem Mass
Spectrometry (LC/LC-MS/MS)—The TMT labeled samples were fractionated by offline
basic pH reverse phase LC, and each of these fractions was analyzed by the acidic pH
reverse phase LC-MS/MS (Wang et al., 2015; Xu et al., 2009). Considering that unmodified
peptides have different elution profiles from phosphopeptides, we performed two offline LC
runs: 5% of the sample for whole proteome (2-3 hr gradient, 40-120 concatenated fractions)
and 95% for phosphoproteome (~1 hr gradient, 40-60 fractions) on an XBridge C18 column
(3.5 μm particle size, 4.6 mm x 25 cm, Waters; buffer A: 10 mM ammonium formate, pH
8.0; buffer B: 95% acetonitrile, 10 mM ammonium formate, pH 8.0) (Bai et al., 2017).
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In the acidic pH LC-MS/MS analysis, each fraction was run sequentially on a column (75
μm x 20-40 cm for the whole proteome, 50 μm x ~30 cm for phosphoproteome, 1.9 μm C18
resin from Dr. Maisch GmbH, 65 °C to reduce backpressure) interfaced with an Q Exactive
HF Orbitrap or Fusion MS (Thermo Fisher). Peptides were eluted by a 2-3 hr gradient
(buffer A: 0.2% formic acid, 5% DMSO; buffer B: buffer A plus 65% acetonitrile). MS
settings included the MS1 scan (410-1600 m/z, 60,000 or 120,000 resolution, 1 x 106 AGC
and 50 ms maximal ion time) and 20 data-dependent MS2 scans (fixed first mass of 120 m/z,
60,000 resolution, 1 x 105 AGC, 100-150 ms maximal ion time, HCD, 35-38% normalized
collision energy, ~1.0 m/z isolation window with 0.3 m/z offset, and ~15 s dynamic
exclusion). For the phosphoproteome analysis, ~1.5 m/z isolation window was used to
improve sensitivity, with 31% stepped normalized collision energy.
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Phosphopeptide Enrichment—The analysis was carried out by TiO2 beads (GL
sciences) as previously reported (Tan et al., 2015). The offline LC fractionated peptides
(~0.15 mg in each fraction) were dried and redissolved in the binding buffer (65%
acetonitrile, 2% TFA, and 1 mM KH2PO4). TiO2 beads (0.6 mg) were washed twice with
the washing buffer (65% acetonitrile, 0.1% TFA), incubated with the peptide fraction at 21
°C for 20 min. The TiO2 beads were washed twice and packed into a C18 StageTip (Thermo
Fisher), followed by the elution of phosphopeptide by the basic pH buffer (15% NH4OH,
and 40% acetonitrile). The eluates were dried and dissolved in 5% formic acid for LCMS/MS analysis.
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Identification of Proteins and Phosphopeptides by Database Search with
JUMP Software—The computational processing of identification was performed with the
JUMP search engine to improve the sensitivity and specificity (Wang et al., 2014). In
general, commercially available software include two major categories of algorithms:
pattern-based scoring (e.g. SEQUEST and MASCOT) and tag-based scoring (e.g. PEAKS).
JUMP combines pattern scoring with de novo tag scoring, displaying significant
improvement in peptide-spectrum match (PSM) scoring (Wang et al., 2014). In this study,
JUMP was used to search MS/MS raw data against a composite target/decoy database (Peng
et al., 2003) to evaluate FDR. All original target protein sequences were reversed to generate
a decoy database that was concatenated to the target database. FDR in the target database
was estimated by the number of decoy matches (nd) and the number of target matches (nt),
according to the equation (FDR = nd/nt), assuming mismatches in the target database were
the same as in the decoy database. The protein database was generated by combining
downloaded Swiss-Prot, TrEMBL, and UCSC databases and removing redundancy (human:
83,955 entries; mouse: 59,423 entries), followed by concatenation with a decoy database.
Major parameters included precursor and product ion mass tolerance (± 15 ppm), full
trypticity, static mass shift for the TMT tags (+229.16293) and carbamidomethyl
modification of 57.02146 on cysteine, dynamic mass shift for Met oxidation (+15.99491)
and Ser/Thr/Tyr phosphorylation (+79.96633), maximal missed cleavage (n = 2), and
maximal modification sites (n = 3). Putative PSMs were filtered by mass accuracy and then
grouped by precursor ion charge state and filtered by JUMP-based matching scores (Jscore
and ΔJn) to reduce FDR below 1% for proteins during the whole proteome analysis or 1%
for phosphopeptides during the phosphoproteome analysis. If one peptide could be
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generated from multiple homologous proteins, based on the rule of parsimony, the peptide
was assigned to the canonical protein form in the manually curated Swiss-Prot database. If
no canonical form was defined, the peptide was assigned to the protein with the highest PSM
number.
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Phosphosite Localization by the JUMPl Program—To evaluate the confidence of
assigned individual phosphosites in peptides, we generated the JUMPl program using the
concept of the phosphoRS algorithm (Taus et al., 2011) to calculate phosphosite localization
scores (Lscore, 0-100%) for each PSM. In addition to the PSM Lscores, all PSMs were
aligned to protein sequences to generate protein Lscores for individual phosphosites. If
multiple PSMs are identified for one specific phosphosite, the highest PSM Lscore is
accepted as the protein Lscore. As random assignment in PSMs containing ambiguous
phosphosites often leads to an excessively large number of protein phosphosites, we
implemented numerous rules to alleviate this problem: (i) in one PSM, if phosphosites can
be clearly distinguished by Lscores (e.g. the gap of the 1st and 2nd PSM Lscores > 10% for
a singly phosphorylated peptide), the top site is selected. (ii) If not, we examined the
phosphosites in the corresponding proteins to select the sites with the top protein Lscore.
This allows the PSMs of low quality to borrow information derived from the PSMs of high
quality. (iii) If neither PSM Lscores nor protein Lscores are distinguishable, a heuristic
priority is given to phosphosites with the following order of occurrence: SP-motif, S, T and
Y. If none of the rules above can sort putative phosphosites, we sort these PSMs by JUMP
Jscores, and then preferentially select protein phosphosites that are previously matched by
other PSMs of high Jscores.
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Proteomics Coverage Analysis—To integrate proteomic and genomic data, we
downloaded human brain transcriptome from The Human Protein Atlas (https://
www.proteinatlas.org/humanproteome/brain) (Uhlen et al., 2015), We extracted 14,548
genes expressed in brain from all human protein-coding genes (n = 19,628 genes). To align
human proteome with transcriptome, we used the UCSC annotation table (http://
hgdownload.cse.ucsc.edu/downloads.html#human) to align UniProt IDs to official gene
symbols. If multiple UniProt IDs match to gene symbols, we choose the UniProt ID of the
most abundant protein.
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Mouse Brain RNA-seq Analysis—Total RNA was isolated from tissue with TRIzol
(Invitrogen) and libraries were prepared using Stranded mRNA Library Prep Kit (Illumina):
double stranded cDNA fragments were ligated with Illumina paired end adaptors, followed
by size selection (~200 bp) and libraries were analyzed by Illumina HiSeq 2000 sequencing
systems. Using BWA (0.5.10) aligner, reads were aligned to multiple databases, including
the mouse reference genome (MGSCv37), transcriptome (RefSeq and AceView) and all
possible combinations of RefSeq exons. Read count for each gene was obtained with HTseq, and the gene-level fragments per kilobase of transcript per million (FPKM) values were
computed.
Immunostaining of Human and Mouse Brain Tissue—The staining was performed
essentially as previously reported (Bai et al., 2013). Briefly, brain tissue samples were fixed
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with 10% formalin, gradual dehydrated, and embedded in paraffin. 7 μm sections were
deparaffinized with CitriSolv Hybrid (5 and 10 min) followed with rehydration with
isopropanol (5 min x 3). Slides were then rinsed with running tap water (5 min) and distilled
water (1 min). Antigen retrieval was performed with 10 mM citric buffer (pH 6.0) with
boiled water bath (20 min) and cool down to 21°C. Slides were then rinsed with running tap
water (5 min), and distilled water (1min), and were blocked the endogenous peroxidase
activity by 1% H2O2 in PBS buffer (10 min). After rinsing by PBS, sections were then
blocked with 10% donkey serum in PBS with 0.3% triton X-100 (PBST) for 30 min at 21
°C. Primary antibodies were diluted with PBST plus 2% BSA and 0.2% skim milk (PBSTB) as follow: MDK (1:100, R&D Systems, Cat# AF-258-PB), NTN1 (1:100, Abcam,
ab126729), human SMOC1 (1:50, MilliporeSigma, Cat# SAB2701398), mouse SMOC1
(1:50, Thermo Fisher Scientific, Cat#PA5-47754), human ICAM1(1:50, Sigma, Cat#
HPA002126), mouse ICAM1(1:100, Abcam, Cat#ab179707), human C4B (1:50, Abcam,
Cat# ab181241). Sections were then incubated with diluted primary antibody at 4 °C
overnight followed with the biotinylated secondary antibody and ABC reaction according to
the instruction of Vectastain ABC kit (Vector Laboratories). After washing with PBS, the
staining was developed by 3,3-diaminobenzidine (DAB) solution (Vector Laboratories) or
Cyanine 3 tyramide (PerkinElmer) for 2-10 min. For double-immunofluorescence staining
with Aβ, sections were incubated with Aβ Ab (82E1,1:100, Immuno-Biological
Laboratories Co., Cat# 10323) followed with secondary antibody conjugated with Alexa
flour 647 (1:500, Jackson ImmunoResearch Laboratories) and DAPI (1 ng/ml, Thermo
Fisher Scientific) for nuclei counter staining. For immunofluorescence staining in human
brain sections, the endogenous fluorescence was eliminated by Sudan Black B staining
(0.1% in 70% ethanol) for 2 min followed by PBS wash. The slides were mounted with
Prolong gold antifade mountant. Fluorescence images were captured by Zeiss LSM 780
confocal microscopy. For the bright field, slides were mounted by Cytoseal 60 (Electron
Microscopy Science), and imaged by Zeiss Axioscan.Z1.
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Aβ Affinity Binding Assay—Biotinylated Aβ40 peptide and scrambled control peptide
(Anaspec), and recombinant proteins (R&D Systems, Novus Biologicals, and eBioscience)
was purchased. Scrambled Aβ peptides were biotinylated using EZ-Link NHS-Biotin
(Thermo Scientific) and tested by binding to streptavidin sepharose beads (GE Healthcare).
The purity of these peptides and recombinant proteins were confirmed by silver-stained SDS
gels. During the binding assay, streptavidin beads (1V = 1 μl bed volume) were used to bind
Aβ and scrambled control (5 μg per peptide) followed by cleaning with 20V of wash buffer
(0.3 x PBS and 0.01% triton X-100). Each peptide-coated column was loaded with one
recombinant protein (0.1 μg/μl, ~1 μg protein), incubated on ice for 30 min, washed with
20V wash buffer, then eluted with 30V of elution buffer (50 mM HEPES, 2% SDS, pH 8.5)
at 95°C. The inputs (10-30 n g) and eluates (~20%) were analyzed by western blotting with
the specific antibodies.
QUANTIFICATION AND STATISTICAL ANALYSIS
TMT-based Peptide/Protein Quantification by JUMP Software Suite—The
analysis was performed in the following steps, as previously reported with modifications
(Niu et al., 2017): (i) extracting TMT reporter ion intensities of each PSM; (ii) correcting the
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raw intensities based on isotopic distribution of each labeling reagent (e.g. TMT126
generates 91.8%, 7.9% and 0.3% of 126, 127, 128 m/z ions, respectively); (iii) excluding
PSMs of very low intensities (e.g. minimum intensity of 1,000 and median intensity of
5,000); (iv) removing sample loading bias by normalization with the trimmed median
intensity of all PSMs; (v) calculating the mean-centered intensities across samples (e.g.
relative intensities between each sample and the mean), (vi) summarizing protein or
phosphopeptide relative intensities by averaging related PSMs; (vii) finally deriving protein
or phosphopeptide absolute intensities by multiplying the relative intensities by the grandmean of three most highly abundant PSMs. In addition, we performed y1-ion based
correction of TMT data.
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Covariate Analysis for Correcting Cell Type Composition Bias—As the
multivariate linear model is commonly used to correct for covariate effects of gene
expression (Miller et al., 2013; Zhang et al., 2013), we used a similar method to correct
individual protein abundance by the cell type composition, including neurons, astrocytes,
microglia, and oligodendrocytes (Figure S8A). Cell type protein markers were selected
based on published cell type resolved mouse proteome (Sharma et al., 2015) by the
following criteria: i) considering mouse-human homologs; ii) selecting cell type enrichment
> 5 fold (except 3 fold for oligodendrocytes due to limited markers) (Figure S8B). The
change of each cell type was estimated as the median of protein abundance across the cell
type markers (Figure S8C, left panel). Before cell type correction, the AD samples showed
a slight increase of microglia and astrocyte, and a slight decrease of neuron and
oligodendrocyte, consistent with the previous proteomics analysis (Seyfried et al., 2017). To
correct for cell type effect, each protein (log-transformed TMT intensity) was fitted to a
linear regression model (requiring ∣β∣ < 1) against the estimated cell type change, and then
adjusted as the residuals plus the intercept (Figure S8C and D). The corrected proteomes
were used for all downstream analyses (e.g., differential expression, network analysis etc.).
Estimation of Measurement Variations—The measurement variation was based on the
replicated measurements of the samples. The relative expression (i.e. ratio) between
replicates for each protein was calculated. The ratios of all proteins from the replicates were
fitted with a Gaussian distribution to estimate expected mean and standard deviation.
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Differential Expression Analysis of Proteins and Phosphopeptides and False
Discovery Rate Evaluation—DE events were defined by identifying proteins/peptides
with intergroup variance significantly larger than intragroup variance using ANOVA
(analysis of variance) as described previously (Tan et al., 2017). Specifically, we applied a
four-step procedure to define DE events as follows: (i) to calculate F statistic for each
protein (defined as the ratio of intragroup variance relative to intergroup variance); (ii) to
apply a threshold of p value (10%); (iii) to capture functionally meaningful changes, we
further filtered the results by the magnitude of change (z score > 2) in one comparison
between AD and other groups and manually examined all proteins, accepting the final list of
DE proteins; (iv) to estimate the final FDR of the accepted DE proteins (p < 10% plus z
score > 2), we performed permutation analysis (n = 1,000 permutations) following a
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reported procedure (Xie et al., 2005) and found that the estimated FDR below 20%. In
addition, DE phosphopeptides were identified by the same method.
Pathway Enrichment by Gene Ontology, KEGG and Hallmark Databases—
Pathway enrichment analysis was carried out to infer functional groups of proteins that were
enriched in a given dataset. The analysis was performed using Fisher’s exact test (p value)
with the BH correction for multiple testing (BH FDR). Enriched pathways with FDR < 20%
or lower were considered statistically significant.
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Principal Component Analysis—Principal component analysis (PCA) was used to
visualize the differences among human disease groups, mouse models, and two
corresponding wild-type controls, as well as human-mouse cross-species comparisons.
Relative expression of all proteins was used as features of PCA. The pairwise Euclidean
distance between features was calculated. PCA was performed using the package prcomp, an
R statistical analysis package (version 3.4.0) (Ihaka and Gentleman, 1996).
Hierarchical Clustering—Hierarchical clustering of differentially expressed (DE)
proteins and phosphopeptides was performed to determine the differences among disease
groups. Hierarchical clustering was carried out using the heatmap.2 function in R statistical
analysis package (version 3.4.0) (Ihaka and Gentleman, 1996). The clustering for heatmap.2
was obtained with Ward's algorithm using Euclidean distance. Disease groups were clustered
and visualized with heat-maps based on the relative expression profiles.
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Weighted Gene Correlation Network Analysis (WGCNA)—The analysis was carried
out with the WGCNA R package (Langfelder and Horvath, 2008). To define whole proteome
clusters (i.e. WPCs), only the DE proteins were considered. Pearson correlation matrix (with
direction, i.e. for building signed correlation network) was calculated using the disease
samples (i.e. LPC, HPC, MCI, and AD), and an adjacency matrix was calculated by raising
the correlation matrix to a power of 16 using the scale-free topology criterion (Zhang and
Horvath, 2005) with modifications. Correlation clusters were defined by hybrid dynamic
tree-cutting method (Langfelder and Horvath, 2008) with the minimum height for merging
modules at 0.2 and manually merged if necessary. For each cluster, a consensus trend was
calculated based on the first principal component (i.e. eigengene). Proteins were assigned to
the most correlated cluster (i.e. WPC) with a cutoff of Pearson correlation coefficient (R) at
least 0.7. Phosphoproteome clusters (PPCs) were also defined by the same procedure.
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Protein-Protein Interaction (PPI) Network Analysis—Proteins in each WPC were
superimposed onto a composite PPI database by combining STRING (v10) (Szklarczyk et
al., 2015), BioPlex (Huttlin et al., 2017), and InWeb_IM (Li et al., 2017). The BioPlex
database was developed by the method of affinity purification and mass spectrometry,
whereas the STRING and InWeb contain information from various sources. Due to this
heterogeneity of PPI interactions, the STRING and InWeb databases were further filtered by
the edge score to ensure high quality, with the following rules: (i) only edges with evidence
of physical interactions (e.g. through co-IP or yeast two-hybrid) were considered; (ii) edges
of high confidence, as filtered by the edge score, with the cutoff determined by best fitting
the log-log degree distribution using the scale free criteria (Barabasi and Oltvai, 2004). The
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finally accepted STRING and InWeb databases were combined with BioPlex to construct a
composite PPI database, which includes 18,515 proteins and 469,993 PPI connections.
Modules in each protein cluster were defined by a two-step procedure: (i) only retaining PPI
edges if both nodes (i.e. the two connected proteins) from proteins in the same cluster; (ii)
calculating a topologically overlapping matrix (Ravasz et al., 2002) for the PPI network, and
modularizing such a network into individual modules by the hybrid dynamic tree-cutting
method (Langfelder and Horvath, 2008). Modules were annotated using three pathway
databases, including Gene Ontology (GO), KEGG and Hallmark by Fisher’s exact test, and
visualized by Cytoscape (Shannon et al., 2003).
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Multi-omics-based Prioritization of Genes/Proteins and Pathways—To integrate
multiple types of datasets for prioritizing genes/proteins in AD, we implemented a gene/
protein ranking framework based on order statistics (Aerts et al., 2006; Zhang et al., 2012),
which combined N different sets of protein/gene rankings to output one protein/gene
ranking. A total of 7 individual datasets of protein/gene ranking were considered for this
analysis:

Author Manuscript

1.

Protein dysregulation in MCI, ranked by the absolute value of log2(MCI/LPC)

2.

Protein dysregulation in AD, ranked by the absolute value of log2(AD/LPC)

3.

Phosphoprotein dysregulation in AD, ranked by the absolute value of log2(AD/
LPC)

4.

Insoluble protein dysregulation in AD, ranked by p values of AD/control (Bai et
al., 2013)

5.

Risk loci identified by GWAS, based on a meta-analysis of 74,046 individuals
provided by The International Genomics of Alzheimer's Project (Lambert et al.,
2013), and summarized into gene level using MAGMA (Katsouras et al., 2015).
This GWAS data was directly obtained from a previous paper (Seyfried et al.,
2017), in which genes were sorted by p values.

6.

Transcriptome data from a previously reported dataset from hundreds of human
cases (Allen et al., 2016).

7.

Interaction strength or closeness (defined by network distance in the PPI
network) to known AD genes: 3 causal genes (APP, PSEN1/2) plus 3 risk genes
(APOE, TREM2, UNC5C) (Scheltens et al., 2016): the shortest paths between
each protein/gene and any AD proteins/genes were computed to obtain the
minimum distance and the most strongly connected AD protein/gene.
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The rank of protein/gene was normalized by the total number of genes/proteins in the
dataset, and only protein/genes with at least four data sources were used. Then, the
integrative protein ranking was generated by the framework of order statistics (Wilks, 1948).
For each protein/gene, the Q statistic was theoretically based on
r1

∫ ∫

Q r1, r2, …, rN = N !

0

r2

s1

∫

…

rN

sN − 1
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Where ri is the rank of each data source i, N is the total number of data sources. In practice,
the Q value was calculated using a more efficient algorithm (Aerts et al., 2006):
Q r1, r2, …, rN = N ! V N

Vk =

k

∑i = 1

−1

i − 1V

k−i i
r
i! N − k + 1

(2)

(3)
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To estimate empirical p values, we used a permutation analysis (Aerts et al., 2006; Zhang et
al., 2012), in which the ranks of each data source were randomly permutated (n = 1,000
times of permutations) to derive null Q values. Empirical p values were derived from the
estimated null distribution, followed by multiple testing correction using the BH method
(Benjamini and Y., 1995).
To summarize the integrative protein/gene ranking into pathway ranking, we identified
dysregulated pathways by GSEA (Subramanian et al., 2005). The p value and FDR were
derived by permuting gene sets (n = 1,000 permutations) in three pathway databases: GO,
KEGG, and Hallmark (all downloaded from the Molecular Signature Database)
(Subramanian et al., 2005). Pathways enriched with FDR < 20% were shown.
DATA AND CODE AVAILABILITY
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Human proteomics data used in this study are available via the AD Knowledge Portal
(https://adknowledgeportal.synapse.org). Additional information can be found via the
following links: the Mount Sinai Brain Bank study (https://adknowledgeportal.synapse.org/
Explore/Studies?Study=syn3159438) and the StJude_Banner study (https://
adknowledgeportal.synapse.org/Explore/Studies?Study=syn21592732). In addition, mouse
and pooled AD proteomics data are available in the PRIDE database (http://
www.proteomexchange.org) with accession numbers of PXD007974 (mouse), PXD018590
(mouse), and PXD007985 (human). An interactive website (https://penglab.shinyapps.io/
ADprofile) was generated to search for individual protein in the AD pooled dataset.
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Refer to Web version on PubMed Central for supplementary material.
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Highlights
•

Deep profiling of proteome and phosphoproteome in AD progression

•

Validation of protein alterations in two independent AD cohorts

•

Identification of Aβ-induced protein changes in AD and the 5xFAD mouse
model

•

Prioritization of proteins and pathways in AD by multi-omics integration
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Figure 1. Whole proteome profiling of AD progression reveals disease stage-dependent proteins/
pathways.
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(A) Strategy for multilayer profiling of proteome and phosphoproteome in AD cases and the
5xFAD mouse model, and multi-omics data integration. The y-axis shows the relative
pathology scores for cognition, plaque, and tangle.
(B) Summary of temporal profiling of five groups of human brain tissue, with each group
containing two independent pools. Each pool contained samples from 9 cases.
(C) MS data showing the Aβ level in each group. The relative TMT intensities of the Aβ
peptide are shown.
(D) Clustering analysis of the proteomics dataset based on the changed proteins. The TMT
intensities (log2 Z-score transformed) of each protein (rows) across five disease groups
(columns) are indicated in a colored scale.
(E) Bioinformatics pipeline for identifying DE proteins followed by clustering and module
analyses.
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(F) Three major clusters (WPC1-3) of DE proteins defined by the WGCNA program. Each
line represent one protein. The intensity of each protein is log2 Z-score transformed (meancentered and scaled by standard deviation). The line color indicates the degree of pattern
correlation between each protein and eigenvalue of the cluster. Proteins discussed in the text
are shown.
(G) Enriched pathways in the WPC proteins by Fisher’s Exact Test. Significantly enriched
pathways (FDR < 20%) are shown.
(H) Detected PPI modules in WPCs.
(I) Validation of selected DE proteins by western blotting with the loading control (tubulin).
See also Figure S1-S3 and Data S1-S3.
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Figure 2. Validation of AD-related proteins by profiling individual human samples in both
Banner Sun and Mount Sinai cohorts
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(A) Analysis of Banner Sun individual cohort. A total of 49 Banner Sun individual cases
were measured with TMT-LC/LC-MS/MS in 5 batches.
(B) Analysis of 80 human cases from Mount Sinai cohort. After removing outliers, 62 cases
(23 controls and 39 AD cases) were analyzed.
(C) Bioinformatics pipeline for validating DE proteins by individual cases from two cohorts.
(D) Validated DE proteins in three datasets (Banner Sun pooled samples, Banner Sun
individual samples, and Mount Sinai individual samples). Each protein is represented by a
colored box after log2 Z-score conversion. The heat map on the far right indicates consistent
(up or down) or inconsistent changes between proteome and transcriptome.
(E) Analysis of CSF samples from Banner Sun cohort. After removing outliers, 5 controls
and 8 AD cases were analyzed.
(F) Consistent protein changes of 8 proteins in AD brain tissue and CSF.
See also Figure S4 and Data S4.
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Figure 3. Profiling of protein phosphorylation events in AD.
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(A) Measurements of Tau phosphorylation by MS. The relative TMT intensities of a
phosphor-Tau peptide in five disease groups are shown.
(B) Distribution of phospho-Ser/Thr/Tyr in the identified phosphosites.
(C) Clustering analysis of the altered phosphopeptides in human samples. The TMT
intensities (log2 Z-score transformed) of phosphopeptides (rows) across five disease groups
(columns) are indicated in a colored scale.
(D) Bioinformatics pipeline for identifying DE phosphopeptides, clustering analysis, and
kinase activity analysis.
(E) Four major phosphoproteome clusters (PPC1-4) of DE phosphopeptides by WGCNA.
Each line represents one phosphopeptide. The line color indicates the degree of pattern
correlation between each phosphopeptide and eigenvalue of the cluster. Phosphoproteins
discussed in the text are shown.
(F) Enriched pathways among the PPC proteins by Fisher’s Exact Test. Significantly
enriched pathways (FDR < 20%) are shown.
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(G) Overlap of DE proteome and phosphoproteome.
(H) Kinase activities computed from related substrates by the IKAP algorithm, with the
absolute abundance of kinase family members shown in a black to white gradient.
(I-J) Substrate phosphorylation levels of specific kinases in four groups of AD samples. The
levels of each phosphosite in the four disease groups (LPC, HPC, MCI and AD) are
represented by boxes filled with red gradients. FC: fold change.
(K) Potential activation of the MAPK pathway based on MS measurements of the whole
proteome and phosphoproteome. The levels of each protein and its phosphosites in the four
groups of human samples (LPC, HPC, MCI and AD) are represented by boxes filled with
red and blue gradients, respectively. The missing values are shown in white boxes.
See also Figure S5, Data S2 and Data S5.
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Figure 4. Aβ-correlated proteins in AD and the 5xFAD mouse model.
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(A) Measurement of Aβ by MS based on its tryptic peptide (red).
(B) Correlation analysis of Aβ and DE proteins in 121 human cases. The degree of
correlation was assessed by Pearson correlation coefficients and corresponding p values.
Proteins were ranked by correlation coefficient values (p < 0.001).
(C) An example protein correlates well with Aβ. The MS measured intensities in samples
were Z-transformed (i.e. mean-centered and scaled by standard deviation).
(D) Analysis of whole proteome in 5xFAD (3, 6, 12 months of age).
(E) human Aβ-correlated proteins validated in 5xFAD, represented by colored boxes after Z
score conversion. The heat map on the far right indicates consistent and inconsistent changes
between proteome and transcriptome in the mice.
See also Data S6.
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Figure 5. Human-mouse proteomic comparison.
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(A) Whole proteome comparison between human cases and 5xFAD. The human HPC, MCI,
and AD data were normalized by LPC, while the 5xFAD results were normalized by WT.
Each dot represents one protein, and the color shows the dot density. Proteins with consistent
changes are shown in the up-right and down-left corners separated by red cutoff lines.
(B) Examples of enriched pathways for human-specific DE proteins. The value of foldchange is indicated by a colored scale.
(C) Examples of activated pathways for 5xFAD-specific DE proteins.
See also Data S6.
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Figure 6. Prioritization of proteins/genes in AD by multi-omics.
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(A) Strategy for ranking proteins and pathways. The proteins were first sorted by integrated
order statistics, and were then used for pathway ranking by gene set enrichment analysis.
(B) The ranking list by combining 7 datasets. In the interactome, each protein was scored by
its distance to the proteins encoded by known AD genes (APP, PSEN1/2, APOE, TREM2,
and UNC5C). The integrative ranks of top 40 proteins are shown by boxes of two color
gradient, while missing values are indicated by white boxes.
(C) Pathway enrichment by GSEA, categorized into four groups. The bar-code plot indicates
the position of the proteins on the sorted rank.
(D) Protein enrichment by subcellular localization.
See also Data S7.
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Figure 7. Characterization of selected protein targets in AD and 5xFAD.
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(A) Immunohistochemistry in human brain sections of control and AD cases (frontal cortex).
Immunoreactivity was developed with DAB chromogen (brown), with counterstaining of
hematoxylin for nuclei (blue). Scale bar: 50 μm.
(B) Immunofluorescence labeling in AD brain sections of the selected proteins (red), Aβ
(green) and nuclei (blue by DAPI). Scale bar: 50 μm.
(C) Immunohistochemistry of the selected proteins in WT and 5xFAD mice (12 month old).
Scale bar = 50 μm.
(D) Immunofluorescence labeling of selected proteins (red), Aβ (green) and nuclei (blue by
DAPI) in 5xFAD cortex (12 month old). Scale bar: 50 μm.
(E) Western blotting in WT and 5xFAD samples (12 month old, hippocampus).
(F) Silver staining of Aβ40 and scramble (Ctl) peptides and human recombinant proteins.
(G) Affinity binding assay between Aβ40 and the recombinant proteins. Aβ40 and scramble
(Ctl) peptides were biotinylated and bound to streptavidin beads packed in mini-columns.
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Individual recombinant proteins were loaded on the columns, followed by wash and elution.
The input and eluate were analyzed by western blotting.
See also Figure S6.
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Characteristics of human subjects used in this study.
Banner Sun pooled samples (n = 90)

Mount Sinai
individual
samples (n = 62)

Banner Sun individual samples (n = 49)

LPC
(n = 18)

HPC
(n = 18)

MCI
(n = 18)

AD
(n = 18)

PSP
(n = 18)

LPC
(n = 12)

HPC
(n = 6)

MCI
(n = 6)

AD
(n = 15)

PSP
(n = 10)

Control
(n = 23)

AD
(n = 39)

83.3±8.0

87.8±5.1

86.4±6.4

75.7±8.7

84.8±11.4

82.9±7.4

87.5±2.7

84.0±8.2

78.0±8.6

83.1±9.5

81±10.4

84±10.1

69–95

78–97

74–98

60–87

59–99

73–95

84–91

74–93

60–87

64–94

61-98

62-103

Male

14

7

9

5

11

9

1

3

6

5

12

12

Female

4

11

9

13

7

3

5

3

9

5

11

27

Mean ± SD

2.8±0.6

2.9±0.8

3.1±0.9

3.3±1.0

2.9±0.6

2.6±0.5

3.0±1.1

3.4±1.0

3.1±0.9

2.6±0.2

9.5±6.3

6.4±4.4

Range

1.5–4.1

1.5–4.3

2.0–5.0

2.0–5.3

2.3–4.3

1.5–3.3

1.5–4.3

2.5–5.0

2.0–5.3

2.3–2.8

1.4-20.3

2.0-20.7

2.2±0.8

3.5±0.5

3.6±0.9

5.6±0.5

3.4±1.1

2.0±0.9

3.5±0.5

3.7±0.8

5.5±0.5

3.7±1.3

1.9±0.8

5.4±1.2

1–3

3–4

2–6

5–6

2–5

1–3

3–4

2–4

5–6

2–5

0-3

2-6

Characteristic
Age (yr)
Mean ± SD
Range
Gender

PMI (hr)
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Braak stage
Mean ± SD
Range
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SOURCE

IDENTIFIER

Anti-Aβ (6E10)

BioLegend

Cat# 803001, RRID:AB_2564653

Anti-Aβ (82E1)

Immuno-biological
laboratories

Cat#010323, RRID:AB_1540460

Anti-C4B

Abcam

Cat# ab181241, RRID:AB_2814770

Anti-CEP63

Abcam

Cat# ab175090

Anti-ICAM1

Cell Signaling

Cat# 4915, RRID:AB_2280018

Anti-ICAM1

MilliporeSigma

Cat#HPA002126, RRID:AB_1078470

Anti-ICAM1

Abcam

Cat#Ab179707, RRID:AB_2814769

Anti-MDK

Thermo Fisher Scientific

Cat# PA5-28823, RRID:AB_2546299

Anti-MDK

R&D Systems

Cat# AF-258-PB, RRID:AB_2143400

Anti-MDK

Abcam

Cat# Ab45151, RRID:AB_2274158

Anti-NTN1

MilliporeSigma

Cat# MABN1154

Anti-NTN1

Abcam

Cat# ab126729, RRID:AB_11131145

Anti-NeuN

MilliporeSigma

Cat# MAB377, RRID:AB_2298772

Anti-OLFML3

Thermo Fisher Scientific

Cat# PA5-49313, RRID:AB_2634767

Anti-PCSK1

MilliporeSigma

Cat#WH0005122M2,
RRID:AB_1843131

Anti-phospho-Tau (AT8)

Thermo Fisher Scientific

Cat# MN1020B, RRID:AB_223648

Anti-RGS4

Abcam

Cat# ab9964, RRID:AB_296731

Anti-SMOC1

MilliporeSigma

Cat# SAB2701398, RRID:AB_2814768

Anti-SMOC1

Thermo Fisher Scientific

Cat# PA5-47754, RRID:AB_2606919

Anti-SQSTM1

Cell Signaling

Cat# 13121, RRID:AB_2750574

Anti-VGF

Abcam

Cat# ab69989, RRID:AB_1271455

Anti-β tubulin

Developmental Studies Hybridoma
Bank

Cat# E7, RRID:AB_528499

Human brain and CSF samples of
postmortem Alzheimer’s disease and
other controls (LPC, HPC, MCI, AD,
and PSP)

Brain and Body
Donation Program at Banner Sun
Health Research Institute

https://www.bannerhealth.com

Human brain samples of postmortem
Alzheimer’s disease and controls

The Mount Sinai/JJ Peters VA
Medical Center Brain Bank
(MSBB–Mount Sinai
NIH Neurobiobank)

https://icahn.mssm.edu/research/nih-brain-tissue-repository

Antibodies

Biological Samples

Author Manuscript

Chemicals, Peptides, and Recombinant Proteins
Aβ40 peptide

Anaspec

Cat# AS-23512

Scrambled peptides

Anaspec

Cat# AS-25383

MDK protein

R&D Systems

Cat# 258-MD-050
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REAGENT or RESOURCE

SOURCE

IDENTIFIER

NTN1 protein

R&D Systems

Cat# 6419N1025

SMOC1 protein

Novus Biologicals, LLC

Cat# 6074-SM-050

ICAM1 protein

eBioscience

Cat# BMS313

TO-PRO-3 Iodide (642/661)

Thermo Fisher Scientific

Cat# T3605

TMT reagents

Thermo Fisher Scientific

Cat# 90110

Interactive proteome data

This paper

https://penglab.shinyapps.io/ADprofile/

Proteomics data of 5xFAD mice and
AD pooled samples in the Banner Sun
cohort

This paper

PPRIDE database (www.proteomexchange.org): with
accession numbers of PXD007974 (mouse), PXD018590
(mouse), and PXD007985 (human).

Proteomics data of AD individual cases
in the Banner Sun and Mount Sinai
cohorts

This paper

The AD Knowledge Portal (https://
adknowledgeportal.synapse.org):
https://doi.org/10.7303/syn21638690
https://doi.org/10.7303/syn21347564

Human brain transcriptome

Allen et al., 2016

https://doi.org/10.7303/syn3163039

5xFAD mouse brain transcriptome

This paper

(https://www.ncbi.nlm.nih.gov/geo/)
GSE140286

Mouse: 5xFAD Tg6799

The Jackson Laboratory

Cat# 34848-JAX

Mouse: C57BL/6J

The Jackson Laboratory

Cat# 000664

JUMP

Wang et al., 2014

http://www.stjuderesearch.org/site/lab/peng

WGCNA

Langfelder et al., 2008

https://labs.genetics.ucla.edu/horvath/
CoexpressionNetwork/Rpackages/WGCNA/

R

R Foundation for Statistical
Computing

https://www.r-project.org/

javaGSEA

Subramanian et al., 2005

http://software.broadinstitute.org/gsea/index.jsp

IKAP

Mischnik et al., 2016

https://github.com/marcel-mischnik/IKAP.git

Deposited Data

Experimental Models: Organisms/Strains

Software and Algorithms
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